UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Gastroenterology (New York, N.Y. 1943), 2020-08, Vol.159 (2), p.521-533.e9

2020

Link zum Volltext

Verfügbarkeit prüfen

Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study

Antiviral research, 2023-08, Vol.216, p.105660-105660, Article 105660

2023

Link zum Volltext

Verfügbarkeit prüfen

A quantitative systems pharmacology model for acute viral hepatitis B

Computational and structural biotechnology journal, 2021-01, Vol.19, p.4997-5007

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778

Antimicrobial agents and chemotherapy, 2018-11, Vol.62 (11)

2018

Link zum Volltext

Verfügbarkeit prüfen

Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

Journal of viral hepatitis, 2020-11, Vol.27 (11), p.1127-1137

2020

Link zum Volltext

Verfügbarkeit prüfen

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB)

Journal of hepatology, 2022-07, Vol.77, p.S838-S839

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Advances in therapy, 2019-09, Vol.36 (9), p.2450-2462

2019

Link zum Volltext

Verfügbarkeit prüfen

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults

Antiviral therapy, 2023-06, Vol.28 (3), p.13596535231172878-13596535231172878

2023

Link zum Volltext

Verfügbarkeit prüfen

FRI-189-HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study

Journal of hepatology, 2019-04, Vol.70 (1), p.e473-e474

2019

Link zum Volltext

Verfügbarkeit prüfen

LBP12 - Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Journal of hepatology, 2020-08, Vol.73, p.S129-S130

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Journal of hepatology, 2020-08, Vol.73, p.S129-S130

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

Antiviral therapy, 2021-05, Vol.26 (3-5), p.58-68

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants

Antiviral therapy, 2023-02, Vol.28 (1), p.13596535231151626

2023

Link zum Volltext

Verfügbarkeit prüfen

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

Clinical pharmacology in drug development, 2022-12, Vol.11 (12), p.1419-1429

2022

Link zum Volltext

Verfügbarkeit prüfen

FRI-198-A Phase, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults

Journal of hepatology, 2019-04, Vol.70 (1), p.e478-e478

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized 5-Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems

Journal of clinical pharmacology, 2012-08, Vol.52 (8), p.1174-1185

2012

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Advances in therapy, 2020-04, Vol.37 (4), p.1703-1703

2020

Link zum Volltext

Verfügbarkeit prüfen

Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance

Journal of pharmacy and pharmacology, 2010-04, Vol.62 (4), p.401-412

2010

Link zum Volltext

Verfügbarkeit prüfen

FRI-217-Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-, in Asian and non-Asian patients with chronic hepatitis B

Journal of hepatology, 2019-04, Vol.70 (1), p.e489-e490

2019

Link zum Volltext

Verfügbarkeit prüfen

Immune network for viral hepatitis B: Topological representation

European journal of pharmaceutical sciences, 2019-08, Vol.136, p.104939, Article 104939

2019

Link zum Volltext

Verfügbarkeit prüfen

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing

SpringerPlus, 2013-01, Vol.2 (1), p.625, Article 625

2013

Link zum Volltext

Verfügbarkeit prüfen

The effect of UGT2B72 polymorphism on the pharmacokinetics of OROS® hydromorphone in Taiwanese subjects

Journal of clinical pharmacology, 2014-10, Vol.54 (10), p.1170-1179

2014

Link zum Volltext

Verfügbarkeit prüfen

Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and Adolescents

Clinical pharmacology in drug development, 2016-09, Vol.5 (5), p.343-353

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Pharmacokinetics of Therapeutic and Supratherapeutic Doses of Tramadol Hydrochloride in Healthy Adults: A Randomized, Double‐Blind, Placebo‐Controlled Multiple‐Ascending‐Dose Study

Clinical pharmacology in drug development, 2017-11, Vol.6 (6), p.592-603

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(19)
Pharmacology & Pharmacy
(14)
Humans
(13)
Hepatitis B
(9)
Adult
(8)
Female
(8)
Pharmacokinetics
(8)
Area Under Curve
(6)
Male
(6)
Analgesics, Opioid - Pharmacokinetics
(5)
Infectious Diseases
(5)
Virology
(5)
Young Adult
(5)
Analgesics, Opioid - Administration & Dosage
(4)
Analgesics, Opioid - Adverse Effects
(4)
Dose-Response Relationship, Drug
(4)
Hepatitis B Virus
(4)
Middle Aged
(4)
Adolescent
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study

A quantitative systems pharmacology model for acute viral hepatitis B

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Effect of Plasma Protein Binding on the Anti-Hepatitis B Virus Activity and Pharmacokinetic Properties of NVR 3-778

Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB)

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults

FRI-189-HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study

LBP12 - Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

FRI-198-A Phase, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults

Randomized 5-Treatment Crossover Study to Assess the Effects of External Heat on Serum Fentanyl Concentrations During Treatment With Transdermal Fentanyl Systems

Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance

FRI-217-Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-, in Asian and non-Asian patients with chronic hepatitis B

Immune network for viral hepatitis B: Topological representation

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing

The effect of UGT2B72 polymorphism on the pharmacokinetics of OROS® hydromorphone in Taiwanese subjects

Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and Adolescents

Safety, Tolerability, and Pharmacokinetics of Therapeutic and Supratherapeutic Doses of Tramadol Hydrochloride in Healthy Adults: A Randomized, Double‐Blind, Placebo‐Controlled Multiple‐Ascending‐Dose Study

Suchergebnisse filtern